CONCLUSION: BB, ACEi/ARB/ARNI and SGLT2i were independently associated with lower risk of all-cause mortality in patients with HFmrEF, specifically when applied as combined “HF triple therapy”. Randomized studies are needed to investigate the effect of HF-related pharmacotherapies in patients with …